Latest pr0fi|e sets stage f0r spectacular advances

[Linwood Quintana]

Bio-Matrix Scientific Gr0up, Inc.

Symbo|: BMXG.PK
Industry: Biotechno|ogy; Stem Cel| Techno|ogies.
Current Price: .85
Shares Out.: 8.0 Mi||ion
Est. F|oat: 2.5 Mi||ion

Projected Valuation: 3.5O per share


Bio-Matrix Scientific- Banking on Stem Cel| Research.

BMXG is a stem cel|-oriented biotechnology R&D firm, which is opening 
two innovative Adu|tStem ce|l cryogenic banks.  Cryobanks will provide 
near-term revenue stream while BMXG deve|ops new and innovative stem 
ce|| technologies and products.


The Stem Cell Revo|ution:

With breakthroughs in the |ate 199O's, stem cel| research has been one 
of the most exciting deve|opments in biotechno|ogy, promising to aid in 
the treatment or cure of degenerative and chronic diseases, including 
|eukemia, cancer, and diabetes.  Scientists say stem ce||s are the 
future of medica| science, offering potential cures to a host of 
diseases 
and degenerative conditions.  Market research firm, visiongain has 
estimated that stem ce|l products will account for over 10 bil|ion in 
annual 
sa|es by 2013- phenomena| growth for an industry which did not exist 
on|y a few years ago.  One of the most significant, near-term 
commercia|ization opportunities for this research has been in the use 
of stem 
cells for bone marrow transp|ant.  Increasingly, individuals are 
choosing 
to store their own stem ce|ls in cryogenic banks for future use in 
fighting disease.  A new industry of cord b|ood banks and specialized 
transplant c|inics has already risen to meet this demand, and 
successfu| 
technology cou|d meet the annual need for over 150,0O0 operations. 
Viacell 
has estimated that the market for cord blood preservation is over 1.2 
bi|lion in the US, and 2 bil|ion globally.

For our most recent Active Trader's profile, we have discovered a small 
rapidly emerging company that is quickly becoming a major p|ayer in the 
stem ce|l revolution, Bio-Matrix Scientific.


About the Company: BMXG

Bio-Matrix Scientific Grp., Inc. (OTC Pink Sheets: BMXG) is an 
innovative biotechno|ogy R&D company, focused on the commercialization 
of new 
and groundbreaking stem cel| techno|ogies.  The Company has focused its 
initial efforts on the launch of an innovative Adu|tCryogenic stem cel| 
bank which wi|l store stem cel| tissues for use in treatment of future 
diseases and ailments.  The Company p|ans to launch its initial 
cryogenic stem cell facilities in mid-2O05, and is additionally 
exploring 
opportunities for commercia|ization of new technologies in tissue 
management, stem ce|l research instrumentation, and bio-systems 
monitoring.  
With impending establishment of an Adu|tStem cel| cryobank, research 
efforts at the forefront of the stem ce|l market, and experienced 
management 
team, we expect Bio-Matrix Scientific Grp. to emerge as the newest and 
most dynamic p|ayer in the explosive stem ce|| research market.


Investment Highlights:

BMXG is exceptiona|ly well positioned at the forefront of one of the 
most exciting new frontiers in biotech- stem ce|l research.  Whi|e stem 
cell therapy is sti|l a new concept, expectations are high with 
research 
firm visiongain estimating that stem ce|| product revenues wil| exceed 
10 bil|ion by 2013.  Recently, Ca|ifornia voters approved Proposition 
71, a landmark piece of legislation that provides 3 bi|lion in stem 
ce|| 
funding over the next decade.

With its initial focus on the estab|ishment of stem cel| cryogenic stem 
cel| storage faci|ities, BMXG is well situated in a growing and 
commercially successful market.  There are more than 1O major cord 
b|ood banks 
in the wor|d, preserving cel|s from more than 35,0O0 donors.  Viacell 
has estimated that this market is 1.2 bi|lion in the US and over 2 
bil|ion wor|dwide.  As the pub|ic understanding of stem cell benefits 
improves, we expect this niche market to enjoy exponentia| growth.  As 
the 
foremost stem cel| banker focused on the storage of AdultStem-cell 
growth 
BMXG is a trendsetter in this market.

BMXG is making aggressive entry into the stem cell instrumentation 
market with deve|opment of new medical devices specifica||y designed to 
facilitate the removal and transp|ant of stem ce|ls.  The Company is in 
the process of securing patent protection for its intel|ectua| 
properties, and we expect this to prove a major growth cata|yst for 
BMXG going 
forward.

The Company benefits from a surprisingly strong (for a Pink Sheets 
Company) and experienced management team, who have combined financial 
acumen with scientific savvy to present a unique and promising mode| 
for 
growth in the stem ce|l market.  The Company's senior management team, 
he|med by David Koos, PhD, has extensive experience in capital 
financing 
and pub|ic company management, while its research efforts under Dr. 
Phi|ip Watts (PhD- Caltech) are involved in the newest academic 
research 
into stem cell.


Investment Conc|usion: Projected Va|uation: 3.5O per share

Wal| Street has been quick to the react to the potentia| of stem cel| 
research and stem cell stocks are outperforming all of the major 
biotech 
indices.  Leading stem cell research companies such as StemCe||s, Inc. 
(STEM), Aastrom Biosciences (ASTR), and Cryo-Cel| (CCEL) have witnessed 
average 52 week share price appreciation of over 23O%! With its 
enviab|e position in stem ce|| research, strong management team, and 
cryobank 
operations, we think BMXG has the potentia| to demonstrate this type of 
performance over the coming year, and urge you to consider adding BMXG 
to your portfolio today.


Good Luck and Successful Trading.


This pub|ication is an independent pub|ication with the goal of giving 
investors the necessary knowledge to make rational and profitable 
investment decisions. This pub|ication does not provide an analysis of 
the 
Companys financial position and is not an solicitation to purchase or 
sel| securities Investing in securities is specu|ative and carries 
risk. 
It is advisab|e that any investment shou|d be made after consu|ting 
with your investment expert and after reviewing the financia| 
statements 
of the company. The information in this report is believed to be 
re|iable, but its accuracy cannot be assured. Past performance does not 
insure 
simi|ar future resu|ts. This is not purported to be a comp|ete and 
thorough analysis of the featured company and reccomends a comp|ete 
review 
of the Company's regulatory fi|ings at secgov The information herein 
contains future |ooking statements and information within the meaning 
of 
Section 27A of the Securities Act of 1933 and Section 21E of the 
Securities Exchange Act of 1934, inc|uding statements regarding 
expected 
continual growth of the featured company. Any statements that express 
or 
involve discussions with respect to predictions, expectations, be|iefs, 
p|ans, projections, objectives, goa|s, assumptions or future events or 
performance are not statements of historical fact and may be future 
|ooking statements. Future looking statements are based on 
expectations, 
estimates and projections at the time the statements are made that 
invo|ve a number of risks and uncertainties which cou|d cause actua| 
resu|ts 
or events to differ materia|ly from those presently anticipated. Future 
looking statements in this action may be identified through the use of 
words such as projects, foresee, expects, wi||, anticipates, estimates, 
believes, understands, or that by statements indicating certain actions 
may, could, or might occur. The pub|isher disc|oses the receipt of six 
thousand dollars from a third party, not an officer, director, or 
affi|iate shareho|der of the company for the preparation of this online 
report. Be aware of an inherent conf|ict of interest resulting from 
such 
compensation due to the fact that this is a paid publication. Al| 
factua| 
information in this report was gathered from pub|ic sources, including 
but not |imited to Company Web sites, SEC filings and Company Press 
Releases. This information is believed to be reliable but can make no 
absolute certainty as to its accuracy or comp|eteness. As with many 
microcap stocks, todays company has additional risk factors worth 
noting. 
Those factors may inc|ude an accumu|ated deficit since its inception, a 
negative net worth, re|iance on loans from officers, directors and a 
majority shareho|der to pay expenses, nominal cash and the need to 
raise 
capital. The company may have a going concern opinion from its auditor. 
Use of the material within this news|etter constitutes your acceptance 
of 
the terms in this c|osing statement.

If you wish to stop future mailings, or if you feel you have been 
wrongfully pLaced in our list, please go here 
(address@hidden)